Recently, Mylan (NASDAQ:MYL) has come under a lot of attention for the price of its Epinephrine Auto-Injector EpiPen. EpiPen price raises left many consumers upset and has even attracted attention from presidential candidates. With the attention surrounding the controversy, however, investors seem to be missing one of the potential biggest beneficiaries of the EpiPen controversy. Two companies are currently working together on another auto-injector for Epinephrine, which could directly compete with the EpiPen. With the increased attention surrounding the issue, it is becoming clear that the public is looking for a cheaper alternative to the EpiPen, and it appears as though Antares Pharmaceuticals (NASDAQ:ATRS) is set to deliver.
EpiPen
Epinephrine has been around for a long time and is the a key treatment for anaphylactic shock. The EpiPen is an auto-injector form of Epinephrine, which is designed to be easy to use for anyone. This helped to bring Epinephrine as a treatment to the masses, as it made it so that anyone could carry Epinephrine on them and almost anyone could inject the drug if needed. This helped to make the EpiPen a drug that is carried around by anyone who is prone to severe allergic reactions. EpiPen has been a very lucrative drug/device comb for Mylan, as it has generated over a billion dollars in sales. Over the last eight years, the wholesale price of the EpiPen has been increased by over 400 percent.
